FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891620699> ?p ?o ?g. }

• W2891620699 endingPage "75" @default.
• W2891620699 startingPage "67" @default.
• W2891620699 abstract "Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate‐to‐severe chronic plaque psoriasis. To consider the benefits and risks of tofacitinib in patients with moderate‐to‐severe psoriasis. Data were pooled from one phase II, four phase III and one long‐term extension study comprising 5204 patient‐years of tofacitinib treatment. Efficacy end points included patients achieving Physician's Global Assessments of ‘clear’ or ‘almost clear’, ≥ 75% and ≥ 90% reduction in Psoriasis Area and Severity Index (coprimary end points) and improvements in Dermatology Life Quality Index score, Hospital Anxiety and Depression Scale depression score and Itch Severity Item score, at weeks 16 and 52. Safety data were summarized for 3 years of tofacitinib exposure. Tofacitinib 5 and 10 mg twice daily (BID) showed superiority over placebo for all efficacy end points at week 16, with response maintained for 52 weeks of continued treatment. Tofacitinib improved patients’ quality of life and was well tolerated. Rates of safety events of interest (except herpes zoster) were similar to those in the published literature and healthcare databases for other systemic psoriasis therapies. Tofacitinib 10 mg BID demonstrated greater efficacy than 5 mg BID. Tofacitinib has a benefit–risk profile in moderate‐to‐severe psoriasis consistent with that of other systemic treatments." @default.
• W2891620699 created "2018-09-27" @default.
• W2891620699 creator A5010367199 @default.
• W2891620699 creator A5027590834 @default.
• W2891620699 creator A5028501480 @default.
• W2891620699 creator A5030758366 @default.
• W2891620699 creator A5035262823 @default.
• W2891620699 creator A5059435575 @default.
• W2891620699 creator A5064403166 @default.
• W2891620699 creator A5067129386 @default.
• W2891620699 creator A5073990067 @default.
• W2891620699 creator A5080374235 @default.
• W2891620699 creator A5085831636 @default.
• W2891620699 creator A5089890051 @default.
• W2891620699 creator A5089961811 @default.
• W2891620699 creator A5091485944 @default.
• W2891620699 date "2018-10-10" @default.
• W2891620699 modified "2023-10-18" @default.
• W2891620699 title "Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials" @default.
• W2891620699 cites W123093596 @default.
• W2891620699 cites W125640847 @default.
• W2891620699 cites W1552422862 @default.
• W2891620699 cites W1890874870 @default.
• W2891620699 cites W1892175722 @default.
• W2891620699 cites W1965730366 @default.
• W2891620699 cites W197305687 @default.
• W2891620699 cites W1987138256 @default.
• W2891620699 cites W2018772902 @default.
• W2891620699 cites W2019695670 @default.
• W2891620699 cites W2028648418 @default.
• W2891620699 cites W2030298480 @default.
• W2891620699 cites W2030972148 @default.
• W2891620699 cites W2039862117 @default.
• W2891620699 cites W2058547807 @default.
• W2891620699 cites W2069350424 @default.
• W2891620699 cites W2087096065 @default.
• W2891620699 cites W2087371579 @default.
• W2891620699 cites W2093455167 @default.
• W2891620699 cites W2096991001 @default.
• W2891620699 cites W2138647255 @default.
• W2891620699 cites W2147568931 @default.
• W2891620699 cites W2158420662 @default.
• W2891620699 cites W2160983874 @default.
• W2891620699 cites W2167305078 @default.
• W2891620699 cites W2176165150 @default.
• W2891620699 cites W2181423112 @default.
• W2891620699 cites W2272200366 @default.
• W2891620699 cites W2283622962 @default.
• W2891620699 cites W2336296838 @default.
• W2891620699 cites W2342884636 @default.
• W2891620699 cites W2400773551 @default.
• W2891620699 cites W2412688745 @default.
• W2891620699 cites W2412722422 @default.
• W2891620699 cites W2584430503 @default.
• W2891620699 cites W2611548364 @default.
• W2891620699 cites W2614093912 @default.
• W2891620699 cites W2621467536 @default.
• W2891620699 cites W2766717228 @default.
• W2891620699 cites W2766846920 @default.
• W2891620699 cites W4240504481 @default.
• W2891620699 cites W798616579 @default.
• W2891620699 cites W99247803 @default.
• W2891620699 doi "https://doi.org/10.1111/bjd.17149" @default.
• W2891620699 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7379291" @default.
• W2891620699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30188571" @default.
• W2891620699 hasPublicationYear "2018" @default.
• W2891620699 type Work @default.
• W2891620699 sameAs 2891620699 @default.
• W2891620699 citedByCount "27" @default.
• W2891620699 countsByYear W28916206992018 @default.
• W2891620699 countsByYear W28916206992019 @default.
• W2891620699 countsByYear W28916206992020 @default.
• W2891620699 countsByYear W28916206992021 @default.
• W2891620699 countsByYear W28916206992022 @default.
• W2891620699 countsByYear W28916206992023 @default.
• W2891620699 crossrefType "journal-article" @default.
• W2891620699 hasAuthorship W2891620699A5010367199 @default.
• W2891620699 hasAuthorship W2891620699A5027590834 @default.
• W2891620699 hasAuthorship W2891620699A5028501480 @default.
• W2891620699 hasAuthorship W2891620699A5030758366 @default.
• W2891620699 hasAuthorship W2891620699A5035262823 @default.
• W2891620699 hasAuthorship W2891620699A5059435575 @default.
• W2891620699 hasAuthorship W2891620699A5064403166 @default.
• W2891620699 hasAuthorship W2891620699A5067129386 @default.
• W2891620699 hasAuthorship W2891620699A5073990067 @default.
• W2891620699 hasAuthorship W2891620699A5080374235 @default.
• W2891620699 hasAuthorship W2891620699A5085831636 @default.
• W2891620699 hasAuthorship W2891620699A5089890051 @default.
• W2891620699 hasAuthorship W2891620699A5089961811 @default.
• W2891620699 hasAuthorship W2891620699A5091485944 @default.
• W2891620699 hasBestOaLocation W28916206991 @default.
• W2891620699 hasConcept C126322002 @default.
• W2891620699 hasConcept C142724271 @default.
• W2891620699 hasConcept C159110408 @default.
• W2891620699 hasConcept C16005928 @default.
• W2891620699 hasConcept C204787440 @default.
• W2891620699 hasConcept C27081682 @default.
• W2891620699 hasConcept C2776173921 @default.

• next